收藏切换
Evaluation of the clinical equivalence of biosimilars to their reference drugs in the treatment of rheumatoid arthritis: a Meta-analysis
收藏切换
Yao CHEN1, 2, Qing-xin ZHOU1, 2, Bao-qi ZENG1, 2, Ji-chun YANG3, Le GAO4, Yu-song YAN1, Feng SUN1, 2
Chinese Journal of New Drugs | 2021, 30(8) : 723 - 731
Less
收藏切换
Chinese Journal of New Drugs | 2021, 30(8): 723-731
Evaluation of the clinical equivalence of biosimilars to their reference drugs in the treatment of rheumatoid arthritis: a Meta-analysis
Full
Yao CHEN1, 2, Qing-xin ZHOU1, 2, Bao-qi ZENG1, 2, Ji-chun YANG3, Le GAO4, Yu-song YAN1, Feng SUN1, 2
Affiliations
  • 1Institute of Public Health, Peking University, Beijing 100191, China
  • 2Peking University Center for Evidence Based Medical and Clinical Research, Beijing 100191, China
  • 3Key Laboratory, the Second Affiliated Hospital of Kunming Medical University, Kunming 650011, China
  • 4Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong 999077, China
Published: 2021-04-30
Outline
收藏切换
Objective:

To demonstrate equivalent clinical efficacy of all biosimilars of adalimumab (ADA), etanercept (ETA), infliximab (INF), and rituximab (RIT) with their reference drugs as well as to evaluate the relative safety and immunogenicity of biosimilars in the treatment of rheumatoid arthritis (RA).

Methods:

Pubmed, Embase, Cochrane Library, Web of Science, Sinomed, ClinicalTrial.gov, CNKI and Wanfang database were searched to collect the randomized controlled trials (RCTs) about the comparisons between biosimilars and their reference drugs for the treatments of RA published from inception to December 17, 2019. Two researchers screened literature, extracted data and assessed risk of bias independently. STATA 15.0 software was used to perform data analysis. To reduce heterogeneity, subgroup analysis in accordance with the drug treatment duration was conducted.

Results:

A total of 27 RCTs were included (ADA: 10, ETA: 6, INF: 7, RIT: 4), involving 10 405 RA patients with inadequate response to the first-line treatment regimen. The clinical efficacy and safety of the four biosimilar drugs were comparable with their reference drugs. In terms of immunogenicity, no statistically significant differences were found between the other three groups except for ETA. It should be noted that the quality rating of the evidence related to the immunogenicity outcome was low, so the results of the immunogenicity need to be further verified by subsequent relevant studies.

Conclusion:

This study supports the similarity of the four biosimilars to their respective reference drugs, which may serve as evidence for related clinical practice, guideline development, and policy making.

biosimilars  /  rheumatoid arthritis  /  randomized controlled trials  /  systematic review  /  Meta-analysis
陈瑶, 周庆欣, 曾保起, 杨继春, 高乐, 颜钰淞, 孙凤. 治疗类风湿关节炎领域生物类似药与其参照药临床相似性评估的Meta分析. 中国新药杂志, 2021 , 30 (8) : 723 -731 .
Yao CHEN, Qing-xin ZHOU, Bao-qi ZENG, Ji-chun YANG, Le GAO, Yu-song YAN, Feng SUN. Evaluation of the clinical equivalence of biosimilars to their reference drugs in the treatment of rheumatoid arthritis: a Meta-analysis[J]. Chinese Journal of New Drugs, 2021 , 30 (8) : 723 -731 .
Year 2021 volume 30 Issue 8
45
10
Cite this Article
BibTeX
Article Info
  • Online Date:2026-10-28
  • Published:2021-04-30
Article Data
Affiliations
History
  • Accepted:2020-03-24
Funding
Affiliations
    1Institute of Public Health, Peking University, Beijing 100191, China
    2Peking University Center for Evidence Based Medical and Clinical Research, Beijing 100191, China
    3Key Laboratory, the Second Affiliated Hospital of Kunming Medical University, Kunming 650011, China
    4Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong 999077, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT